Purification and Functional Characterization of Alpha-1-Antitrypsin for Autoimmune Disease Intervention
DOI:
https://doi.org/10.54097/2vdybk76Keywords:
Alpha-1-Antitrypsin; autoimmune disease; type 1 diabetes.Abstract
Type 1 diabetes (T1D) is an autoimmune disease mediated by autoreactive T cells. Current treatments primarily target symptom control and struggle to fundamentally regulate the abnormal immune response. Therefore, developing novel biotherapeutic strategies that combine immunomodulation and tissue protection is crucial. Recent studies have shown that alpha-1 antitrypsin (AAT) can delay or even reverse disease progression in non-obese diabetic mice and improve transplanted islet survival, demonstrating its potential for treating autoimmune diseases. This article systematically reviews the gene structure, biological function, and the impact of N-glycosylation on the activity of AAT. It focuses on analyzing the production advantages of CHO cell-derived recombinant AAT (rAAT) and key technologies such as ion exchange chromatography, affinity chromatography, and continuous purification. The study demonstrates that CHO cells can achieve glycosylation modifications close to those of natural AAT, and a multi-step chromatographic strategy can yield high-purity, high-activity rAAT products. In the future, the purification process should be further optimized, the functional evaluation system should be improved, and its therapeutic value in T1D and other autoimmune diseases should be verified through clinical research, so as to provide a theoretical basis for the development of novel immunomodulatory biological agents.
Downloads
References
[1] Atkinson, M. A., Eisenbarth, G. S., Michels, A. W. Type 1 diabetes[J]. The Lancet, 2014, 383(9911): 69–82. https://doi.org/10.1016/S0140-6736(13)60591-7. DOI: https://doi.org/10.1016/S0140-6736(13)60591-7
[2] Bluestone, J. A., Herold, K., Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes[J]. Nature, 2010, 464(7293): 1293–1300. https://doi.org/10.1038/nature08933. DOI: https://doi.org/10.1038/nature08933
[3] Guttman, O., et al. Acute-phase protein alpha-1-antitrypsin: diverting injurious innate and adaptive immune responses from non-authentic threats[J]. Clinical and Experimental Immunology, 2015, 179(2): 161–172. https://doi.org/10.1111/cei.12476. DOI: https://doi.org/10.1111/cei.12476
[4] Koulmanda, M., et al. Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(38): 15443–15448. https://doi.org/10.1073/pnas.1018366109. DOI: https://doi.org/10.1073/pnas.1018366109
[5] Lewis, E. C., et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105(42): 16236–16241. https://doi.org/10.1073/pnas.0807627105. DOI: https://doi.org/10.1073/pnas.0807627105
[6] Bruni, R., et al. Recombinant production of alpha-1-antitrypsin: recent advances and challenges[J]. Frontiers in Bioengineering and Biotechnology, 2017, 5: 11. https://doi.org/10.3389/fbioe.2017.00011. DOI: https://doi.org/10.3389/fbioe.2017.00011
[7] Brantly, M., Nukiwa, T., Crystal, R. G. Molecular basis of alpha-1-antitrypsin deficiency[J]. The American Journal of Medicine, 1988, 84(6A): 13–31. https://doi.org/10.1016/0002-9343(88)90154-4. DOI: https://doi.org/10.1016/0002-9343(88)90154-4
[8] Perlmutter, D. H., Pierce, J. A. The alpha 1-antitrypsin gene and its expression in cells of the monocyte/macrophage lineage[J]. Chest, 1989, 95(Suppl 3): 114S–119S. https://doi.org/10.1378/chest.95.3_supplement.114s.
[9] Huber, R., Carrell, R. W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins[J]. Biochemistry, 1989, 28(23): 8951–8966. https://doi.org/10.1021/bi00449a001. DOI: https://doi.org/10.1021/bi00449a001
[10] Lomas, D. A., et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver[J]. Nature, 1992, 357(6379): 605–607. https://doi.org/10.1038/357605a0. DOI: https://doi.org/10.1038/357605a0
[11] Lewis, E. C. Expanding the clinical indications for alpha (1)-antitrypsin therapy[J]. Molecular Medicine, 2012, 18(1): 957–970. https://doi.org/10.2119/molmed.2011.00196. DOI: https://doi.org/10.2119/molmed.2011.00196
[12] Bergin, D. A., et al. Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8[J]. Journal of Clinical Investigation, 2010, 120(12): 4236–4250. https://doi.org/10.1172/JCI41196. DOI: https://doi.org/10.1172/JCI41196
[13] Petrache, I., et al. Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis[J]. American Journal of Pathology, 2006, 169(4): 1155–1166. https://doi.org/10.2353/ajpath.2006.060058. DOI: https://doi.org/10.2353/ajpath.2006.060058
[14] Bluestone, J. A., et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells[J]. Science Translational Medicine, 2010, 2(46): 46ra62. https://doi.org/10.1126/scitranslmed.3001511.
[15] Zhang, B., et al. Alpha1-antitrypsin protects beta-cells from apoptosis[J]. Diabetes, 2007, 56(5): 1316–1323. https://doi.org/10.2337/db06-1273. DOI: https://doi.org/10.2337/db06-1273
[16] Mega, T., et al. The glycosylation sites of alpha-1-antitrypsin[J]. Biochemistry, 1980, 19(18): 4196–4202. https://doi.org/10.1021/bi00559a009. DOI: https://doi.org/10.1021/bi00559a009
[17] Dycaico, M. J., et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model[J]. Science, 1988, 242(4884): 1409–1412. https://doi.org/10.1126/science.3264419. DOI: https://doi.org/10.1126/science.3264419
[18] Yel, L., et al. Alpha-1-antitrypsin deficiency and the role of inflammation in clinical outcome[J]. Allergy and Asthma Proceedings, 2010, 31(1): 17–23. https://doi.org/10.2500/aap.2010.31.3291.
[19] Jayapal, K. P., et al. Recombinant protein therapeutics from CHO cells – 20 years and counting[J]. Chemical Engineering Progress, 2007, 103(10): 40–47.
[20] Carta, G., Jungbauer, A. Protein Chromatography: Process Development and Scale-Up[M]. Weinheim: Wiley-VCH, 2010. ISBN: 978-3-527-31819-3. DOI: https://doi.org/10.1002/9783527630158
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

